Methods and compositions that affect melanogenesis

Details Methods and compositions that affect melanogenesis Methods and compositions that affect melanogenesis

2006-04-20

2009-10-20

Aeder, Sean E (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

Reexamination Certificate

active

07604949

ABSTRACT:
The invention provides methods of screening for compounds that affect melanogenesis and the function of P protein in organisms, cells, or cell-free systems. The invention further relates to pharmacologic and cosmetic uses of methods of inhibiting melanogenesis, methods of activating melanogenesis, and compounds and pharmacologic compositions useful for the inhibition or activation of melanogenesis and, therefore, for lightening or darkening the pigmentation of cells and tissue, i.e., skin.

REFERENCES:
patent: 3062846 (1962-11-01), Fried
patent: 3155591 (1964-11-01), Hilfer et al.
patent: 3210386 (1965-10-01), Birkenmeyer et al.
patent: 3389051 (1968-06-01), Kagan et al.
patent: 3755560 (1973-08-01), Dickert et al.
patent: 3929678 (1975-12-01), Laughlin et al.
patent: 3959461 (1976-05-01), Bailey et al.
patent: 4139619 (1979-02-01), Chidsey, III
patent: 4278656 (1981-07-01), Nagai et al.
patent: 4369174 (1983-01-01), Nagai et al.
patent: 4387090 (1983-06-01), Bolich, Jr.
patent: 4421769 (1983-12-01), Dixon et al.
patent: 4439432 (1984-03-01), Peat
patent: 4684635 (1987-08-01), Orentreich et al.
patent: 4935352 (1990-06-01), Igarashi et al.
patent: 4959313 (1990-09-01), Taketo
patent: 4959393 (1990-09-01), Torihara et al.
patent: 5011681 (1991-04-01), Ciotti et al.
patent: 5073371 (1991-12-01), Turner et al.
patent: 5073372 (1991-12-01), Turner et al.
patent: 5120532 (1992-06-01), Wells et al.
patent: 5151209 (1992-09-01), McCall et al.
patent: 5151210 (1992-09-01), Steuri et al.
patent: 5214028 (1993-05-01), Tomita et al.
patent: 5232917 (1993-08-01), Bolger et al.
patent: 5302517 (1994-04-01), Rhode, III
patent: 5389611 (1995-02-01), Tomita et al.
patent: 5512483 (1996-04-01), Mader et al.
patent: 5569678 (1996-10-01), Lee
patent: 5580549 (1996-12-01), Fukuda et al.
patent: 5591423 (1997-01-01), Fuller
patent: 5616332 (1997-04-01), Herstein
patent: 5627033 (1997-05-01), Smith et al.
patent: 5628987 (1997-05-01), Fuller
patent: 5665578 (1997-09-01), Gillies
patent: 5681744 (1997-10-01), Greenstein
patent: 5686103 (1997-11-01), Redziniak et al.
patent: 5691380 (1997-11-01), Mason et al.
patent: 5789215 (1998-08-01), Berns et al.
patent: 5811260 (1998-09-01), Miyazaki et al.
patent: 5814618 (1998-09-01), Bujard et al.
patent: 5827687 (1998-10-01), Koyama et al.
patent: 5840525 (1998-11-01), Vandlen et al.
patent: 5849997 (1998-12-01), Grosveld et al.
patent: 5851984 (1998-12-01), Matthews et al.
patent: 5861290 (1999-01-01), Goldsmith et al.
patent: 5968528 (1999-10-01), Deckner et al.
patent: 5993835 (1999-11-01), Mishima et al.
patent: 6123959 (2000-09-01), Jones et al.
patent: 6132740 (2000-10-01), Hu
patent: 6139854 (2000-10-01), Kawato
patent: 6159482 (2000-12-01), Tuloup et al.
patent: 6197830 (2001-03-01), Frome
patent: 0 993 826 (2000-04-01), None
patent: 0 993 826 (2000-04-01), None
patent: 0 997 140 (2000-05-01), None
patent: 0 997 140 (2000-05-01), None
patent: 8-337528 (1996-12-01), None
patent: WO-88/09810 (1988-12-01), None
patent: WO-90/11364 (1990-10-01), None
patent: WO-97/00892 (1997-01-01), None
patent: WO-98/37897 (1998-09-01), None
patent: WO-98/49999 (1998-11-01), None
patent: WO-99/04752 (1999-02-01), None
patent: WO-99/09011 (1999-02-01), None
patent: WO-99/32077 (1999-07-01), None
patent: WO-99/56740 (1999-11-01), None
patent: WO-99/64025 (1999-12-01), None
patent: WO-00/56702 (2000-09-01), None
patent: WO-00/58549 (2000-10-01), None
patent: WO-00/62742 (2000-10-01), None
patent: WO-00/76473 (2000-12-01), None
patent: WO-01/01131 (2001-01-01), None
patent: WO-02/49580 (2002-06-01), None
Kim et al (Int. J. Cancer, 2006, 118:1670-1679).
Hall et al (Pigment Cell Research, 2003, 16:149-158).
McCurdy (J. Cell Bio., 1969, 43(2):220-228).
Seiberg et al (J. Invest. Dermatol., 2000, 115(2):162-167).
Imokawa (Jul. 1989, Journal of Investigative Dermatology, 93(1):100-7).
Dennell (May 1949, Proceedings of the Royal Society of London, 136(882): 94-109).
Rosemblat et al (Mar. 1998, Experimental Cell Research, 239:344-352).
Palumbo et al (Mar. 1997, Biochem J, 323:749-756).
Lamoreux et al (Oct. 1995, Pigment Cell Research, 8(5): 263-70).
Borovansky et al (Feb. 1997, Arch Dermatol Res, 289: 145-150).
The Merck Index, 12thEdition (1996, Merck & Co., Inc., Whitehouse Station, N.J., pp. 581, 845, 1154, 1358 and 1656).
Blanchette-Mackie E. J. “Intraceullular cholesterol trafficking: role of the NCP1 protein”Biochemica and Biophysica Acta. Molecular and Cell Biology of Lipids, Elsevier, Amsterdam, NL. vol. 1486, No. 1, Jun. 2000. pp. 171-183.
Haermaelae A. S. et al. “Cholesterol Transport from Plasma Membranes to Intracellular Membranes is Inhibited by 3-Beta-(2-(Diethylamino)Ethoxy)and Rost-5-en-17-one”Biochemica et Biophysica Acta—Lips and Lipid Metabolism, Elsevier Science BV Amsterdam, NL. vol. 1211, No. 3, Mar. 1994, pp. 317-325.
Lange Y et al. “Cholesterol Movement in Niemann-Pick Type C Cells and in Cells Treated with Amphiphiles.”Journal of Biological Chemistry, American Society of Biochemical Biologists, Birmingham, U.S. vol. 275, No. 23, Jun. 9, 2000. pp. 17468-17475.
Lange Y. et al. “Cholesterol Homeostatis Modulation By Amphiphiles.” Journal of Biological Chemistry, American Society of Biochemical Biologists, Birmingham, US. vol. 269, No. 47, Nov. 1994. pp. 29371-29374.
Liscum L. et al. “Intracellular Cholesterol Transport.”Journal of Lipid Research1999. United States, vol. 33, No. 9, 1992. pp. 1239-1254.
Supplemental, Partial European Search Report, corresponding to European Application No. 02776548.6, mailed Nov. 27, 2007, 4 pages.
Vippagunta et al. “Crystalline solids” Advanced Drug Delivery Reviews 48 (2001) 3-26.
Abdel-Malek, et al., “Mitogenic, Melanogenic and cAMP Responses of Cultured Neonatal Human Melanocytes to Commonly Used Mitogens”, Journal of Cellular Physiology, 150:416-425 (1992).
Adams, et al., “The c-myc Oncogene Driven by Immunoglobulin Enhancers Induces Lymphoid Malignancy in Transgenic Mice”, 318:533-538 (1985).
Alexander, et al., “Expression of the c-myc Oncogene Under Control of an Immunoglobulin Enhancer in Eu-myc Transgenic Mice”, Molecular and Cellular Biology, 7(4):1436-1444 (1987).
Ancans, et al., “Activation of Melanogenesis by Vacuolar Type H4+-ATPase Inhibitors in Amelanotic, Tyrosinase Positive Human and Mouse Melanoma Cells”, FEBS Letters, 478:57-60 (2000).
Ansel, et al.Pharmaceutical Dosage Forms and Drug Delivery Systems, Sixth Ed., A Lea & Febiger Book, Williams & Wilkins, Baltimore (1995).
Bayer, et al., EMBASE 1998386460, J. Virology, 72(12):9645-9655 (1998) (Abstract).
Bennett, et al., “Line of Non-Tumorigenic Mouse Melanocytes . . . ”, Int. J. Cancer, 39:414-418 (1987).
Benoist, et al., “In Vivo Sequence Requirements of the SV40 Early Promoter Region”, Nature, 290:304-310 (1981).
Bouchard, et al., “Induction of Pigmentation in Mouse Fibroblasts by Expression of Human Tyrosinase cDNA”, J. Exp. Med., 169:2029-2042 (1989).
Bowman, et al, “Bafilomycins: a Class of Inhibitors of Membrane ATPases From Microorganisms . . . ”, Proc. Natl. Acad. Sci., 85:7972-7976 (1988).
Brilliant, et al., “Anatomy of Pigment Cell Genes Acting at the Cellular Lever”, inThe Pigmentary System: Physiology and Pathophysiology, Norlund, et al., eds., Oxford University Press, Chapter 18, pp. 217-229 (1998).
Brinster, et al., “Regulation of Methallothionein-thymidine Kinsase Fusion Plasmids Injected into Mouse Eggs”, Nature, 296:39-42 (1982).
Chakraborty, et al., “Effect of Arbutin on Melanogenic Proteins in Human Melanocytes”, Pigment Cell Research, 11:206-212 (1998).
Chang, et al., “Rat Gene Encoding the 78-kDa Glucose-Regulated Protein GRP78”, Porc. Natl. Acad. Sci., 84:680-684 (1987).
Cohen, et al., Psychiat. Res. Repts., 1:11-13 (1995) Abstract.
Deboer, et al., “The tac Promoter: a Functional Hybrid Derived from the trp and iac Promoters”, Proc. Natl. Acad. Sci., 80

Affiliated with

Also associated with

Rating

Methods and compositions that affect melanogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions that affect melanogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions that affect melanogenesis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4083019